Devonian Health Group Inc. (DVHGF)
- Previous Close
0.1689 - Open
0.1713 - Bid --
- Ask --
- Day's Range
0.1689 - 0.1689 - 52 Week Range
0.1597 - 0.2138 - Volume
200 - Avg. Volume
3 - Market Cap (intraday)
25.035M - Beta (5Y Monthly) 1.53
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0200 - Earnings Date Jun 30, 2024 - Jul 4, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Devonian Health Group Inc. engages in the development of botanical drugs. Its lead product candidate is Thykamine, completed Phase IIa clinical trial product for the treatment of ulcerative colitis and atopic dermatitis. The company also develops Pantoprazole Magnesium for the treatment of gastric; Cleo-35 for the treatment of hormonal acne in women; and value-added products for dermo-cosmetics. In addition, the company acquires drug and health product licenses; and distributes pharmaceutical products. Devonian Health Group Inc. was incorporated in 2015 and is headquartered in Québec, Canada.
groupedevonian.comRecent News: DVHGF
Performance Overview: DVHGF
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: DVHGF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: DVHGF
Valuation Measures
Market Cap
26.99M
Enterprise Value
26.37M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
6.56
Price/Book (mrq)
2.61
Enterprise Value/Revenue
5.24
Enterprise Value/EBITDA
-7.74
Financial Highlights
Profitability and Income Statement
Profit Margin
-85.08%
Return on Assets (ttm)
-13.59%
Return on Equity (ttm)
-30.22%
Revenue (ttm)
5.03M
Net Income Avi to Common (ttm)
-4.28M
Diluted EPS (ttm)
-0.0200
Balance Sheet and Cash Flow
Total Cash (mrq)
1M
Total Debt/Equity (mrq)
1.15%
Levered Free Cash Flow (ttm)
-1.59M
Company Insights: DVHGF
DVHGF does not have Company Insights